NEW YORK, NY / ACCESSWIRE / July 31, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Fred's, Inc. (NASDAQGS:FRED)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/freds-inc-loss-submission-form?prid=2705&wire=1
Lead Plaintiff Deadline: August 27, 2019
Class Period: December 20, 2016 to June 28, 2017
According to the filed complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.
Netflix, Inc. (NASDAQGS:NFLX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netflix-inc-loss-submission-form?prid=2705&wire=1
Lead Plaintiff Deadline: September 20, 2019
Class Period: April 17, 2019 to July 17, 2019
Allegations against NFLX include that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Mallinckrodt Public Limited Company (NYSE:MNK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?prid=2705&wire=1
Lead Plaintiff Deadline: September 24, 2019
Class Period: February 28, 2018 to July 16, 2019
Allegations against MNK include that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong